Vinva Investment Management Ltd Has $23.91 Million Stake in AbbVie Inc. $ABBV

Vinva Investment Management Ltd raised its position in AbbVie Inc. (NYSE:ABBV) by 40.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 131,133 shares of the company’s stock after purchasing an additional 37,656 shares during the quarter. AbbVie accounts for approximately 0.6% of Vinva Investment Management Ltd’s holdings, making the stock its 29th largest holding. Vinva Investment Management Ltd’s holdings in AbbVie were worth $23,907,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ABBV. Safe Harbor Fiduciary LLC bought a new position in shares of AbbVie during the second quarter worth about $418,000. Te Ahumairangi Investment Management Ltd boosted its position in AbbVie by 15.5% during the 2nd quarter. Te Ahumairangi Investment Management Ltd now owns 23,830 shares of the company’s stock worth $4,423,000 after acquiring an additional 3,190 shares during the last quarter. Choreo LLC grew its stake in shares of AbbVie by 0.5% during the 2nd quarter. Choreo LLC now owns 108,650 shares of the company’s stock worth $20,168,000 after acquiring an additional 487 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of AbbVie by 1.5% in the second quarter. Russell Investments Group Ltd. now owns 1,167,382 shares of the company’s stock valued at $216,491,000 after purchasing an additional 16,700 shares during the last quarter. Finally, Maia Wealth LLC raised its holdings in shares of AbbVie by 2.2% in the second quarter. Maia Wealth LLC now owns 3,113 shares of the company’s stock valued at $578,000 after purchasing an additional 67 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $227.57 on Thursday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company’s 50 day moving average price is $227.51 and its two-hundred day moving average price is $206.27. The firm has a market cap of $402.20 billion, a PE ratio of 108.37, a PEG ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the prior year, the business posted $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Daiwa Capital Markets raised shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 target price for the company in a research report on Thursday, August 7th. Evercore ISI raised their price objective on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and upped their target price for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Morgan Stanley raised their price target on AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Finally, Guggenheim upped their price objective on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $241.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.